It is proposed that this article be deleted because of the following concern:
If you can address this concern by improving, copyediting, sourcing, renaming, or merging the page, please edit this page and do so. You may remove this message if you improve the article or otherwise object to deletion for any reason. Although not required, you are encouraged to explain why you object to the deletion, either in your edit summary or on the talk page. If this template is removed, do not replace it . The article may be deleted if this message remains in place for seven days, i.e., after 15:13, 22 December 2025 (UTC). Find sources: "PANACREAS" – news · newspapers · books · scholar · JSTOR Nominator: Please consider notifying the author/project: {{ subst:proposed deletion notify |PANACREAS|concern=Topic of the article fails Wikipedia's [[WP:N|notability guidelines]] <small>(relevant information may be found on the talk page)</small>}} ~~~~ |
Another editor has reviewed this page's proposed deletion , endorses the proposal to delete, and adds: If you remove the {{proposed deletion/dated}} tag above, please also remove this {{Proposed deletion endorsed}} tag. |
 | This article needs additional citations for verification .(June 2023) |
 Integrating chemical approaches to treat pancreatic cancer: making new leads for a cure | |
| Funding | |
|---|---|
| European Commission Seventh Framework Programme | |
| Project | |
| Collaborative project | |
| Grant agreement N° | |
| 256986 | |
| Starting date | |
| March1st, 2011 | |
| Duration | |
| 5 years | |
| Website | |
| http://www.panacreas.eu [1] | |
| Participants | |
| UKB | Universitaetsklinikum Bonn [2] (coordinator) (GERMANY) |
| UNIGE | Università degli Studi di Genova [3] (ITALY) |
| CSIC | Agencia Estatal Consejo Superior de Investigaciones Cientificas [4] (SPAIN) |
| EPFL | École Polytechnique Fédérale de Lausanne [5] (SWITZERLAND) |
| CHUV | University Hospital of Lausanne [6] (SWITZERLAND) |
| USE | Universidad de Sevilla [7] (SPAIN) |
| UNITN | Università degli Studi di Trento [8] (ITALY) |
| SIB | Swiss Institute of Bioinformatics [9] (SWITZERLAND) |
| ULUND | Lunds Universitet [10] (SWEDEN) |
| DEBIO | Debiopharm SA [11] (SWITZERLAND) |
| Apointech | Apointech S.L. [12] (SPAIN) |
| ALTA | ALTA S.r.l.u. [13] (ITALY) |
PANACREAS stands for "Integrating chemical approaches to treat pancreatic cancer: making new leads for a cure" and is being supported through Coordination Theme 1 (Health) of the European Community's FP7.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies and a major health problem. It has been estimated that PDAC causes 34,000 deaths per year in the EU alone. [14] Despite considerable research efforts in the past decades, conventional treatment approaches, including surgery, radiation, chemotherapy, and combinations of these, have close to no impact on the course of this aggressive neoplasm. Therefore, virtually all of the patients diagnosed with PC develop metastases and die. [15] Given this scenario, the search for new drugs to combat PDAC progression and thus increase patient life expectancy and quality of life has been given high priority. [16] In particular, the National Cancer Institute's Gastrointestinal Cancer Steering Committee has recently place major emphasis on the enhancement of "research to identify and validate the relevant targets and molecular pathways in PDAC, cancer stem cells, and the microenvironment";